Author

Astrid Scalori

Observed names: A Scalori, A. Scalori

Observed institutions: University of Pisa, Roche (Switzerland), Genentech, King's College London, University of Milan, Queen Mary Hospital, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Azienda Ospedaliera Bolognini Seriate, Azienda Ospedaliera di Valtellina e Valchiavenna, Azienda Ospedaliera San Gerardo, King's College Hospital NHS Foundation Trust, Roche (United Kingdom), King's College Hospital, University of Milano-Bicocca, University of Hong Kong

OpenAlex ID: A5018910016

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · The Lancet. Gastroenterology & hepatology · 97

PDF

Oral contraceptives and the risk of focal nodular hyperplasia of the liver: A case-control study

2002 · Astrid Scalori, Alessandra Tavani, et al. · American Journal of Obstetrics and Gynecology · 90

Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells #

2009 · Maria Serena Longhi, Ragai R. Mitry, et al. · Hepatology · 89

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients

1998 · Luigi Roffi, Alessandra Ricci, et al. · Journal of Hepatology · 82

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

2023 · Vivek Subbiah, Mimi I. Hu, et al. · Thyroid · 63

PDF

Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study

2012 · Stratigoula Sakellariou, Hussa Al‐Hussaini, et al. · Histopathology · 44

Interferon-induced depression: prevalence and management

2004 · A. Scalori, M. Pozzi, et al. · Digestive and Liver Disease · 41

Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test

2000 · Astrid Scalori, Paolo Apale, et al. · European Journal of Gastroenterology & Hepatology · 36

Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype

2001 · Luigi Roffi, Alessandro Redaelli, et al. · European Journal of Gastroenterology & Hepatology · 35

Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study

2002 · Astrid Scalori, Alessandra Tavani, et al. · The American Journal of Gastroenterology · 30

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study

2025 · S. Peters, R. Camidge, et al. · Annals of Oncology · 29

PDF

Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis

2015 · Ingvar Bjarnason, Bu Hayee, et al. · EBioMedicine · 26

PDF

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

2014 · Jordan J. Feld, Ira M. Jacobson, et al. · Journal of Hepatology · 21

A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT

2019 · Stéphane Jouneau, Anne-Sophie Gamez, et al. · Respiration · 19

PDF

Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.

2022 · Aaron Scott Mansfield, Vivek Subbiah, et al. · Journal of Clinical Oncology · 10

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

2021 · Wenhui Zhang, Astrid Scalori, et al. · Inflammatory Bowel Diseases · 10

PDF

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

2016 · Heiner Wedemeyer, Xavier Forns, et al. · PLoS ONE · 10

PDF

Psychological screening before interferon therapy

2001 · Astrid Scalori, Paolo Apale, et al. · Hepatology · 6

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

2016 · Edward J. Gane, Régine Rouzier, et al. · Hepatology International · 5

Psychological Screening Before Interferon Therapy

2001 · Astrid Scalori, Paolo Apale, et al. · Hepatology · 5

PDF

1787MO Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)

2025 · R. Dziadziuszko, B.J. Solomon, et al. · Annals of Oncology · 3

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

2024 · Kit Wun Kathy Cheung, Yang Tang, et al. · Pharmaceutics · 3

PDF

1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)

2022 · M.I. Hu, V. Subbiah, et al. · Annals of Oncology · 3

PDF

OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)

2024 · H. Horinouchi, B.J. Solomon, et al. · Journal of Thoracic Oncology · 2

PDF

LBA1 Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA

2023 · J.S. Ahn, Y-L. Wu, et al. · Annals of Oncology · 2

PDF

Works count: 56

Citation count: 774

H-index: 14

I10-index: 17